126 related articles for article (PubMed ID: 7081293)
1. The genetics of malignant hyperthermia: evidence for heterogeneity.
McPherson E; Taylor CA
Am J Med Genet; 1982 Mar; 11(3):273-85. PubMed ID: 7081293
[TBL] [Abstract][Full Text] [Related]
2. Several interacting genes influence the malignant hyperthermia phenotype.
Robinson R; Hopkins P; Carsana A; Gilly H; Halsall J; Heytens L; Islander G; Jurkat-Rott K; Müller C; Shaw MA
Hum Genet; 2003 Feb; 112(2):217-8. PubMed ID: 12522565
[TBL] [Abstract][Full Text] [Related]
3. Multiple interacting gene products may influence susceptibility to malignant hyperthermia.
Robinson RL; Curran JL; Ellis FR; Halsall PJ; Hall WJ; Hopkins PM; Iles DE; West SP; Shaw MA
Ann Hum Genet; 2000 Jul; 64(Pt 4):307-20. PubMed ID: 11415515
[TBL] [Abstract][Full Text] [Related]
4. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
[TBL] [Abstract][Full Text] [Related]
5. The King syndrome: malignant hyperthermia, myopathy, and multiple anomalies.
McPherson EW; Taylor CA
Am J Med Genet; 1981; 8(2):159-65. PubMed ID: 7282770
[TBL] [Abstract][Full Text] [Related]
6. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree.
Moslehi R; Langlois S; Yam I; Friedman JM
Am J Med Genet; 1998 Feb; 76(1):21-7. PubMed ID: 9508059
[TBL] [Abstract][Full Text] [Related]
7. [Muscular enzyme level disorders and a malignant hyperthermia susceptability test: postoperative study of a patient with elevated CPK].
Perugini M; Montironi C; Rocchi S
Minerva Anestesiol; 1998; 64(1-2):45-50. PubMed ID: 9658790
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of disposition for malignant hyperthermia--an updated review based on 1,001 studies].
Olthoff D; Deutrich C; Meinecke CD
Anaesthesiol Reanim; 1997; 22(2):32-40. PubMed ID: 9235003
[TBL] [Abstract][Full Text] [Related]
9. Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue.
Bachand M; Vachon N; Boisvert M; Mayer FM; Chartrand D
Can J Anaesth; 1997 Jul; 44(7):696-701. PubMed ID: 9232296
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.
Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A
Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia.
Marchant CL; Ellis FR; Halsall PJ; Hopkins PM; Robinson RL
Muscle Nerve; 2004 Jul; 30(1):114-7. PubMed ID: 15221887
[TBL] [Abstract][Full Text] [Related]
14. Increasing the number of diagnostic mutations in malignant hyperthermia.
Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
Heytens L
Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
[TBL] [Abstract][Full Text] [Related]
16. [Current aspects of the diagnosis of malignant hyperthermia].
Rüffert H; Olthoff D; Deutrich C; Froster UG
Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
[TBL] [Abstract][Full Text] [Related]
18. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.
Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V
Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Mendelian disorders to common chronic disease: opportunities for recognition, intervention, and prevention.
Scheuner MT; Yoon PW; Khoury MJ
Am J Med Genet C Semin Med Genet; 2004 Feb; 125C(1):50-65. PubMed ID: 14755434
[TBL] [Abstract][Full Text] [Related]
20. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores.
Quane KA; Keating KE; Healy JM; Manning BM; Krivosic-Horber R; Krivosic I; Monnier N; Lunardi J; McCarthy TV
Genomics; 1994 Sep; 23(1):236-9. PubMed ID: 7829078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
